Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Feedback ( (GB:FDBK) ).
Feedback plc reported half-year results to 30 November 2025 showing stable revenue of £0.41m, with Bleepa contributing the majority, but a higher EBITDA loss of £1.61m as the company invested in support teams and cloud infrastructure. Cash fell to £3.82m, though management said the business has sufficient funding through mid‑2027 and remains financially stable while laying the groundwork to scale in 2026–27.
Operationally, Feedback advanced the positioning of Bleepa through key NHS integrations, expanded clinical pathways at Queen Victoria Hospital and participation in national neighbourhood health simulations that demonstrated potential reductions in outpatient appointments and unplanned admissions. The company has submitted a national business case for Bleepa under the NHS Spending Review, is in late‑stage talks with strategic partners and sees alignment with the NHS 10‑Year Plan as a catalyst for potential material contracts that could significantly accelerate its growth and strengthen its role in digital healthcare infrastructure.
The most recent analyst rating on (GB:FDBK) stock is a Hold with a £10.50 price target. To see the full list of analyst forecasts on Feedback stock, see the GB:FDBK Stock Forecast page.
Spark’s Take on GB:FDBK Stock
According to Spark, TipRanks’ AI Analyst, GB:FDBK is a Neutral.
The score is held down primarily by deteriorating financial performance (sharp revenue decline, very large/worsening losses, and ongoing cash burn), partially offset by a debt-free balance sheet. Technicals add modest support due to an upward trend, but extremely overbought signals raise near-term risk. Valuation provides limited support given negative earnings and no dividend yield data.
To see Spark’s full report on GB:FDBK stock, click here.
More about Feedback
Feedback plc is a UK-based clinical infrastructure specialist focused on digital connectivity and asynchronous collaboration in healthcare. Its flagship SaaS platform, Bleepa, is an award‑winning collaboration tool that links disparate systems to streamline patient pathways, support the shift to community-based care and drive productivity across public and private markets, including the NHS.
The company targets domestic and international healthcare providers with scalable, integration‑ready software designed to improve care coordination. By uniting data and teams and embedding into core NHS systems, Feedback aims to unlock operational efficiencies and deliver recurring, visibility‑enhancing revenue as its customer base grows.
Average Trading Volume: 90,483
Technical Sentiment Signal: Sell
Current Market Cap: £4.71M
For detailed information about FDBK stock, go to TipRanks’ Stock Analysis page.